Nitrogen In Aglycone Moiety Patents (Class 536/17.4)
-
Patent number: 8809285Abstract: The present invention provides for monophosphorylated lipid A derivatives and carbohydrate derivatives that are useful as agents in the treatment of diseases and conditions, including cancers. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I-IV. In addition, methods for the treatment of cancers are provided.Type: GrantFiled: July 30, 2010Date of Patent: August 19, 2014Assignee: Wayne State UniversityInventors: Zhongwu Guo, Qianli Wang, Shouchu Tang
-
Publication number: 20140228551Abstract: The invention provides D02S derivatives conjugated to monosaccharide ligands directly or through a linker and optionally chelated to a metal, wherein the D02S derivatives having the following structure: wherein R1?, R2? are each independently —OH or —O-alkyl; R1 is a hydrogen, a linker, or a ligand; R3 is a linker and/or a ligand; and n is an integer from 1 to 10; the linker is an amino acid, a peptide, an amino alcohol, a polyethylylene glycol, an alkyl, an alkenyl, an alkynyl, an azide, an aromatic compound, a carboxylic acid, or an ester, the alkyl, alkenyl, or alkynyl is optionally substituted with an alkyl, a halogen, a nitro group, a hydroxyl group, an amino group, or a carboxyl group; the ligand is a GLUT1 targeting moiety.Type: ApplicationFiled: June 20, 2012Publication date: August 14, 2014Applicant: RadioMedix Inc.Inventors: Izabela Tworowska, Jennifer Sims-Mourtada, Ebrahim S. Delpassand
-
Publication number: 20140228310Abstract: Disclosed are methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of at least one p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the at least one p38 MAPK by the compound. Also disclosed are derivatives of pirfenidone. These derivatives can modulate a stress activated protein kinase (SAPK) system.Type: ApplicationFiled: April 28, 2014Publication date: August 14, 2014Applicant: InterMune, Inc.Inventors: Lawrence M. Blatt, Scott D. Seiwert, Leonid D. Beigelman, Ramachandran Radhakrishnan, Karl Kossen, Vladimir Serebryany
-
Patent number: 8802832Abstract: This invention relates generally to compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier.Type: GrantFiled: August 4, 2011Date of Patent: August 12, 2014Assignee: DemeRx, Inc.Inventors: Deborah C. Mash, Richard D. Gless, Jr.
-
Publication number: 20140213538Abstract: Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one or more of the lysophosphatidic acid receptors are provided.Type: ApplicationFiled: January 15, 2014Publication date: July 31, 2014Inventors: Brad Owen Buckman, John Beamond Nicholas, Kumaraswamy Emayan, Scott D. Seiwert, Shendong Yuan
-
Patent number: 8791246Abstract: An inventive substrate is provided which includes a substrate compound of formula A-B1-B2-B3-B4: wherein A is a sugar moiety; B1 is a linker moiety allowing the conjugation of moiety A and the remaining structure of the substrate; B2 is a linker moiety with a free reactive amino group so as to be available for reaction with carboxylic acids or detectable tags; B3 contains a permanently charged element such as a quaternary ammonium group so as to increase sensitivity for mass spectrometry analysis; and B4 of various carbon length conferring specificity amongst individual substrates in detection methods. Also provided is a molecule of the formula B1-B2-B3-B4, with similar structural characteristics to an enzymatic product produced by the action of a target enzyme on an inventive substrate. Further provided are methods for using inventive substrates for detecting enzymatic activity.Type: GrantFiled: April 3, 2012Date of Patent: July 29, 2014Assignee: PerkinElmer Health Sciences, Inc.Inventors: Blas Cerda, Mark Norman Bobrow
-
Patent number: 8785404Abstract: The present invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof.Type: GrantFiled: September 25, 2013Date of Patent: July 22, 2014Assignee: Eli Lilly and CompanyInventor: Fucheng Qu
-
Patent number: 8785608Abstract: The invention relates to crystalline hydrates of the formula I in which n has a value of from 2.1 to 2.5. The compound is suitable, for example, as an antidiabetic.Type: GrantFiled: August 26, 2010Date of Patent: July 22, 2014Assignee: SanofiInventors: David Rigal, Franceska Fischer, Bernd Becker, Martin Feth, Norbert Nagel, Bruno Baumgartner, Martin Bröeckelmann
-
Patent number: 8778893Abstract: The present invention is directed to metabolites of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-ol, the compound of formula (I), pharmaceutical compositions thereof, and to methods of using the metabolites and the pharmaceutical compositions in the treatment of cancer.Type: GrantFiled: October 4, 2010Date of Patent: July 15, 2014Assignee: Bristol-Myers Squibb CompanyInventors: Jiachang Gong, Lisa J. Christopher, Vinod Kumar Arora
-
Patent number: 8778628Abstract: An arylalkylamine compound is represented by the following formula [I-e] or a pharmaceutically acceptable salt thereof.Type: GrantFiled: June 17, 2013Date of Patent: July 15, 2014Assignee: Mitsubishi Tanabe Pharma CorporationInventors: Hiroshi Miyazaki, Junko Okabe, Kosuke Yasuda, Iwao Takamuro, Osamu Sakurai, Tetsuya Yanagida, Yutaka Hisada
-
Patent number: 8772463Abstract: Disclosed are a novel fluorescent glucose analogue, a method for the synthesis thereof and the use thereof. The novel fluorescent glucose analogue is labeled with fluorescent dye by O-1-glycosylation and via various linkers. The fluorescent glucose analogue can be applied to molecular bioimaging and a method for screening curative or preventive drugs for glucose metabolism-related diseases.Type: GrantFiled: September 7, 2010Date of Patent: July 8, 2014Assignee: SNU R&DB FoundationInventors: Seung Bum Park, Hyang Yeon Lee, Jong Min Park
-
Publication number: 20140187506Abstract: The present invention provides compounds of the formula, wherein A, B, G, R2, R6, and X are defined herein, pharmaceutical compositions of the same, and methods for treating or inhibiting development of AGE- and/or ALE-associated complications in subjects in need thereof.Type: ApplicationFiled: February 20, 2014Publication date: July 3, 2014Applicant: NephroGenex, Inc.Inventors: Raja G. Khalifah, Roger E. Marti
-
Publication number: 20140187499Abstract: The invention relates to substituted anionic compounds consisting of a backbone made up of a discrete number u of between 1 and 8 (1?u?8) of identical or different saccharide units, linked via identical or different glycosidic bonds, said saccharide units being chosen from the group consisting of pentoses, hexoses, uronic acids, N-acetylhexosamines in cyclic form or in open reduced form, which are randomly substituted. It also relates to the process for the preparation thereof and to the pharmaceutical compositions comprising same.Type: ApplicationFiled: November 13, 2013Publication date: July 3, 2014Inventors: Gérard SOULA, Emmanuel DAUTY, Richard CHARVET
-
Patent number: 8748401Abstract: The present invention provides hydroxyl, keto, and glucuronide derivatives of 3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile.Type: GrantFiled: June 13, 2013Date of Patent: June 10, 2014Assignee: Incyte CorporationInventors: James D. Rodgers, Adam Shilling, Argyrios G. Arvanitis, Stacey Shepard, Laurine G. Galya, Mei Li, Frank M. Nedza
-
Publication number: 20140147938Abstract: The present invention relates to a non covalent molecular structure comprising a carbon nanostructure and a pyrene based glycoconjugate (I) which is linked to the said carbon nanostructure by a non covalent link, the said glycoconjugate (I) having the formula: wherein B is a group which is present on any of the ten carbon atoms of the pyrene structure represented in (I) susceptible to bear a substituent, and is represented by the following group: —(CH2)n-CO—NH-A, wherein n is an integer from 1 to 9, A is a group of formula: The present invention also relates to an electronic device comprising the said non covalent molecular structure, and to the use of this device for the detection of a lectin involved in bacterial or viral infections. Thus the invention also relates to a method for detecting the presence of a lectin in a sample to be analysed.Type: ApplicationFiled: July 12, 2011Publication date: May 29, 2014Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), University of Pittsburgh-Of the Commonwealth System of Higher Education, INSA LYON, UNIVERSITE CLAUDE BERNARD LYON 1 (UCBL)Inventors: Anne Imberty, Sébastien Vidal, Alxander Star
-
Patent number: 8735557Abstract: Derivatives of PSAs are synthesized, in which a reducing and/or non-reducing end terminal sialic acid unit is transformed into a N-hydroxysuccinimide (NHS) group. The derivatives may be reacted with substrates, for instance substrates containing amine or hydrazine groups, to form non-cross-linked/crosslinked polysialylated compounds. The substrates may, for instance, be therapeutically useful drugs, peptides or proteins or drug delivery systems.Type: GrantFiled: July 9, 2012Date of Patent: May 27, 2014Assignee: Lipoxen Technologies LimitedInventors: Sanjay Jain, Ioannis Papaioannou, Smita Thobhani
-
Publication number: 20140142132Abstract: The present invention provides a compound of formula I: wherein R1, R2, R2? and X? are as defined and described herein, methods of manufacture thereof and compositions thereof, useful for example as peripheral mu opioid receptor antagonists in treatment of side effects of opioid administration.Type: ApplicationFiled: September 4, 2013Publication date: May 22, 2014Applicants: WYETH, LLC, PROGENICS PHARMACEUTICALS, INC.Inventors: Alfred A. Avey, Appavu Chandrasekaren, Harold D. Doshan, Julio Perez, Yakov Rotshteyn
-
Patent number: 8716252Abstract: Provided are (methylsulfonyl)ethyl benzene isoindoline compounds, and pharmaceutically acceptable salts, solvates, or stereoisomers thereof. Methods of use and pharmaceutical compositions of these compounds are also disclosed.Type: GrantFiled: December 21, 2010Date of Patent: May 6, 2014Assignee: Celgene CorporationInventors: Peter H. Schafer, Anthony J. Frank, Hon-Wah Man, Sai L. Shankar
-
Publication number: 20140113878Abstract: This invention relates generally to compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier.Type: ApplicationFiled: August 4, 2011Publication date: April 24, 2014Inventors: Deborah C. Mash, Richard D. Gless, JR.
-
Patent number: 8703720Abstract: Compounds having an effect as i.a. galectin inhibitors, to the use of said compounds as a medicament, as well as for the manufacture of a medicament for treatment of disorders relating to the binding of galectin to receptors in a mammal, where in the galectin is preferably a galectin-3.Type: GrantFiled: April 26, 2010Date of Patent: April 22, 2014Assignee: Galecto Biotech ABInventors: Hakon Leffler, Ulf J. Nilsson, Henrik Von Wachenfeldt
-
Patent number: 8703721Abstract: The present invention relates to an arylalkylamine compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, a process for preparing the same, and use of the above-mentioned compound as an activating compound (CaSR agonist) of a Ca sensing receptor, a pharmaceutical composition containing the above-mentioned compound as an effective ingredient, etc.Type: GrantFiled: May 12, 2011Date of Patent: April 22, 2014Assignee: Mitsubishi Tanabe Pharma CorporationInventors: Hiroshi Miyazaki, Junko Tsubakimoto, Kosuke Yasuda, Iwao Takamuro, Osamu Sakurai, Tetsuya Yanagida, Yutaka Hisada
-
Publication number: 20140105932Abstract: This invention relates to synthetic oligo- or multivalent beta-1-2-linked mannooligosaccharide compounds and to their use for modulating T helper (Th) and T regulatory (Treg) cell-mediated immune responses.Type: ApplicationFiled: June 21, 2012Publication date: April 17, 2014Applicants: Åbo Akademi University, Turun yliopistoInventors: Johannes Savolainen, Kaarina Ranta, Reko Leino, Chinmoy Mukherjee
-
Publication number: 20140107044Abstract: The invention provides compounds for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.Type: ApplicationFiled: March 16, 2012Publication date: April 17, 2014Applicants: Merck Sharp & Dohme Corp., Alectos Therapeutics Inc.Inventors: Ernest J. McEachern, David J. Vocadlo, Yuanxi Zhou, Craig A. Coburn, Kun Liu, Harold G. Selnick
-
Publication number: 20140107327Abstract: This disclosure relates to a method that involves reacting an azide with an alkyne in the presence of deuterated water and a copper-containing catalyst, thereby forming a deuterated 1,2,3-triazole.Type: ApplicationFiled: March 26, 2012Publication date: April 17, 2014Applicant: RESEARCH FOUDATION OF THE CITY UNIVERSITY OF NEW YORKInventors: Mahesh K. Lakshman, Hari Kiran Akula
-
Patent number: 8697849Abstract: The present invention provides a compound of Formula II: wherein X represents the following: or a pharmaceutically acceptable salt thereof.Type: GrantFiled: May 2, 2013Date of Patent: April 15, 2014Assignee: Eli Lilly and CompanyInventors: Fucheng Qu, Nathan Bryan Mantlo
-
Publication number: 20140100179Abstract: The present invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: September 25, 2013Publication date: April 10, 2014Applicant: Eli Lilly and CompanyInventor: Fucheng QU
-
Publication number: 20140100178Abstract: A system for selectively delivering drugs to target tissues is provided. The system includes a drug-linker-saccharide-drug conjugate (D-L-A-D1). The linker includes a functional group that is recognized and cleaved by enzyme in the target phases. The recognition segment is preferably a malaria drugs. The carrier is preferably hydrophilic, biodegradable and biocompatible particle. Any drug may be delivered using a conjugate prepared according to the invention.Type: ApplicationFiled: October 4, 2012Publication date: April 10, 2014Inventors: Aslam Ansari, Sanjay Gupta
-
Publication number: 20140088028Abstract: The invention provides compounds of formula (I) with substituents as specified in Claim 1 for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceuticals compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to over-expression of O-GlcNAcase or accumulation of O-GlcNac.Type: ApplicationFiled: March 20, 2012Publication date: March 27, 2014Inventors: Ramesh Kaul, Ernest J. McEachern, David J. Vocadlo, Yuanxi Zhou, Kun Liu, Harold G. Selnick, Zhongyong Wei, Changwei Mu, Yaode Wang, Xiaona Wang
-
Publication number: 20140088029Abstract: Provided is a novel therapeutic means for Alzheimer's disease. In particular, provided is a compound represented by the following general formula (I): [wherein Ar1 represents 2-methoxy-4-(2-pyridylmethoxy)phenyl etc. and Ar2 represents a 1H-indol-6-yl group etc.] or a salt thereof.Type: ApplicationFiled: April 11, 2012Publication date: March 27, 2014Applicant: PHARMA EIGHT CO., LTD.Inventors: Hachiro Sugimoto, Michiaki Okuda, Takashi Takahashi, Ichiro Hijikuro, Hidetaka Suzuki, Shinichi Nakayama
-
Patent number: 8679854Abstract: The present invention relates to a fluorescent dye-labeled glucose analog, and a synthesis method and usage of the same, and more particularly, to novel glucose ? and ? anomers in which a fluorescent dye is labeled by O-1-glycosylation, an asymmetric synthesis method of the anomers, a molecular bioimaging method of the anomers, and a screening method of curing or preventing drugs for diseases related to glucose metabolism.Type: GrantFiled: December 21, 2007Date of Patent: March 25, 2014Assignee: SNU & DB FoundationInventors: Seung Bum Park, Myung Haing Cho, Hyang Yeon Lee, Jong Min Park
-
Publication number: 20140080770Abstract: An arylalkylamine compound is represented by the following formula [I-e] or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: June 17, 2013Publication date: March 20, 2014Applicant: Mitsubishi Tanabe Pharma CorporationInventors: Hiroshi MIYAZAKI, Junko OKABE, Kosuke YASUDA, Iwao TAKAMURO, Osamu SAKURAI, Tetsuya YANAGIDA, Yutaka HISADA
-
Publication number: 20140081010Abstract: This invention describes processes for the convergent synthesis of calicheamicin derivatives, and similar analogs using bifunctional and trifunctional linker intermediates.Type: ApplicationFiled: September 12, 2013Publication date: March 20, 2014Applicant: WYETH LLCInventors: Justin Keith MORAN, Jianxin GU
-
Publication number: 20140045778Abstract: Disclosed is a composition for use as a pest control agent, comprising a compound represented by formula (I) or an agriculturally and horticulturally acceptable salt thereof as active ingredient and an agriculturally and horticulturally acceptable carrier:Type: ApplicationFiled: January 3, 2013Publication date: February 13, 2014Applicants: THE KITASATO INSTITUTE, MEIJI SEIKA PHARMA CO., LTD.Inventors: MEIJI SEIKA PHARMA CO., LTD., THE KITASATO INSTITUTE
-
Patent number: 8642756Abstract: Disclosed herein are nucleoside phosphoramidates and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent 5 RNA viral replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication and for treatment of hepatitis C infection in mammals.Type: GrantFiled: May 20, 2010Date of Patent: February 4, 2014Assignee: Gilead Pharmasset LLCInventors: Bruce Ross, Michael Joseph Sofia, Ganapati Reddy Pamulapati, Suguna Rachakonda, Hai-Ren Zhang, Byoung-Kwon Chun, Peiyuan Wang
-
Publication number: 20140031535Abstract: Ligand Drug conjugate compounds comprising a ?-glucuronide-based linker and methods of using such compounds are provided.Type: ApplicationFiled: September 25, 2013Publication date: January 30, 2014Applicant: Seattle Genetics, Inc.Inventor: Scott Jeffrey
-
Patent number: 8637648Abstract: This invention relates generally to compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier.Type: GrantFiled: June 21, 2011Date of Patent: January 28, 2014Assignee: Demerx, Inc.Inventors: Deborah C. Mash, Robert M. Moriarty
-
Publication number: 20140018309Abstract: The invention provides compounds with enhanced permeability for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.Type: ApplicationFiled: December 21, 2011Publication date: January 16, 2014Applicants: MERCK SHARP & DOHME CORP., ALECTOS THERAPEUTICS, INC.Inventors: Ramesh Kaul, Ernest J. Mceachern, Changwei Mu, Harold G. Selnick, David J. Vocadlo, Yaode Wang, Zhongyong Wei, Yuanxi Zhou, Yongbao Zhu
-
Publication number: 20140011988Abstract: This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of formula (I) wherein Q, J, L and Z are as defined in the specification.Type: ApplicationFiled: February 14, 2013Publication date: January 9, 2014Inventors: Robert Deziel, Silvana Leit, Patrick Beaulieu, Yves Andre Chantigny, John Mancuso, Pierre Tessier, Gideon Shapiro, Richard Chesworth, David Smil
-
Publication number: 20140005371Abstract: A caprazene compound is provided which is the compound represented by the following formula (Ia): wherein Me stands for methyl group, and A is a hydrogen atom, and wherein said compound has the 1H-NMR and 13C-NMR data as set forth in Table 15.Type: ApplicationFiled: July 12, 2013Publication date: January 2, 2014Inventors: Toshiaki MIYAKE, Masayuki IGARASHI, Tetsuo SHITARA, Yoshiaki TAKAHASHI, Masa HAMADA
-
Publication number: 20130345157Abstract: The present invention provides hydroxyl, keto, and glucuronide derivatives of 3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile.Type: ApplicationFiled: June 13, 2013Publication date: December 26, 2013Applicant: INCYTE CORPORATIONInventors: James D. Rodgers, Adam Shilling, Argyrios G. Arvanitis, Stacey Shepard, Laurine G. Galya, Mei Li, Frank M. Nedza
-
Publication number: 20130331350Abstract: Compounds, compositions and methods are provided for inhibiting in vitro and in vivo processes mediated by E-selectin binding. More specifically, particular glycomimetic compounds are described, wherein the compounds are E-selectin antagonists.Type: ApplicationFiled: September 12, 2011Publication date: December 12, 2013Applicant: GLYCOMIMETICS, INC.Inventors: Beat Ernst, Céline E. Weckerle, Jonas K. Egger
-
Publication number: 20130331349Abstract: The present invention relates to compounds of Formula (I), a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesiod X receptors (FXR).Type: ApplicationFiled: November 30, 2011Publication date: December 12, 2013Inventors: David C. Tully, Paul Vincent Rucker, Phillip B. Alper, Daniel Mutnick, Donatella Chianelli
-
Publication number: 20130324531Abstract: There are provided compounds of the formula wherein X, Y, Z, R1, R2 and R3 are as described herein and enantiomers and pharmaceutically acceptable salts and esters thereof. The compounds are useful as anticancer agents.Type: ApplicationFiled: May 29, 2013Publication date: December 5, 2013Applicant: Hoffmann-La Roche Inc.Inventors: David Joseph Bartkovitz, Xin-Jie Chu, George Kenneth Ehrlich, Jin-Jun Liu, Hanspeter Michel, Binh Thanh Vu, Chunlin Zhao
-
Patent number: 8598132Abstract: Glycosylated indolocarbazoles, method for obtaining same and uses thereof. This invention relates to rebeccamycin and staurosporine derivatives obtained by fermentation of recombinant bacterial strains. The invention also relates to the methods used to obtain the recombinant strains and the production of rebeccamycin and staurosporine derivatives. The invention also relates to bacterial strains that are of use for the production of rebeccamycin and staurosporine derivatives. Lastly, the rebeccamycin and staurosporine derivatives described herein are applicable to the field of human health, specifically for manufacturing drugs that are of use in the treatment of tumour, neurological and inflammatory diseases.Type: GrantFiled: April 6, 2009Date of Patent: December 3, 2013Assignees: Universidad de Oviedo, Entrechem, S.L.Inventors: Aaroa Pérez Salas, César Sánchez Reillo, Alfredo Fernández Braña, Carmen Méndez Fernández, Jose Antonio Salas Fernández, Francisco Morís Varas
-
Patent number: 8592383Abstract: The invention provides certain cycloalkyl-fused tetrahydroquinolines of the Formula (I), and their pharmaceutically acceptable salts and esters, wherein R1, R2, R7, R8, R8a, E, Y, Z, n, u, and t are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions associated with uncontrolled or inappropriate stimulation of CRTH2 function.Type: GrantFiled: June 14, 2012Date of Patent: November 26, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: Xianhai Huang, Jason Brubaker, Scott L. Peterson, John W. Butcher, Joshua T. Close, Michelle Martinez, Rachel Nicola MacCoss, Joon O. Jung, Phieng Siliphaivanh, Hongjun Zhang, Robert G. Aslanian, Purakkattle Johny Biju, Li Dong, Ying Huang, Kevin D. McCormick, Anandan Palani, Ning Shao, Wei Zhou
-
Publication number: 20130303471Abstract: The present invention provides a compound of Formula II: wherein X represents the following: or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: May 2, 2013Publication date: November 14, 2013Applicant: Eli Lilly and CompanyInventors: Fucheng QU, Nathan Bryan MANTLO
-
Publication number: 20130281387Abstract: Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administering a composition comprising a chemosensory receptor ligand. Also provided herein are chemosensory receptor ligand compositions and methods for the preparation thereof for use in the methods of the present invention.Type: ApplicationFiled: October 18, 2011Publication date: October 24, 2013Applicant: ELCELYX THERAPEUTICS, INC.Inventors: Alain D. Baron, Martin R. Brown, Christopher R.G. Jones, Nigel R.A. Beeley
-
Patent number: 8551914Abstract: Molecules having the following structure are disclosed. Processes of using such molecules are disclosed.Type: GrantFiled: August 25, 2011Date of Patent: October 8, 2013Assignee: Dow AgroSciences, LLC.Inventors: Lawrence C. Creemer, Gary D. Crouse, Thomas C. Sparks, CaSandra Lee McLeod
-
Patent number: 8551960Abstract: The invention relates to the use of certain derivatives of D-mannopyranoside for controlling angiogenesis. These compounds have a pro-angiogenic activity, and can particularly be used for preparing a pharmaceutical composition for treating cardiovascular diseases or for treating muscular atrophy. The invention also relates to certain D-mannopyranoside derivatives, to a pharmaceutical or cosmetic composition containing said derivatives, and to the use of such a cosmetic composition for preventing and/or treating hair loss.Type: GrantFiled: May 5, 2009Date of Patent: October 8, 2013Assignee: Centre National de la Recherche ScientifiqueInventors: Jean-Louis Montero, Véronique Montero, Jean-Pierre Moles, Pascal De Santa Barbara, Bernard Jover
-
Publication number: 20130252268Abstract: The present invention relates to the visualization of acidic organelles based upon organelle enzyme activity. The organelle substrates of the invention are specific for enzyme activity of the organelle and label these organelles, such as lysosomes, rendering them visible and easily observed. Substrates of the present invention include substrates that produce a fluorescent signal. The fluorogenic acidic organelle enzyme substrates of this invention are designed to provide high fluorescence at low pH values and are derivatized to permit membrane permeation through both outer and organelle membranes of intact cells and can be used for staining cells at very low concentrations. They can be used for monitoring enzyme activity in cells at very low concentrations and are not toxic to living cells or tissues.Type: ApplicationFiled: May 14, 2013Publication date: September 26, 2013Applicant: Marker Gene Technologies, Inc.Inventors: John J. Naleway, Daniel J. Coleman